Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy

Circulation Journal

Volumn 75, Issue 9, 2011, Pages 2160-2166

  Tsutamoto, Takayoshi ^a,b   Sakai, Hiroshi ^b   Ibe, Kunihiro ^a   Yamaji, Masayuki ^b   Kawahara, Chiho ^b   Nakae, Ichiro ^b   Fujii, Masanori ^b   Yamamoto, Takashi ^b   Horie, Minoru ^b  

^a Toyosato Hospital   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Cardiac sympathetic nerve activity; Heart failure; Metaiodobenzylguanidine; N terminal pro B type natriuretic peptide; Statin

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROHORMONE; NORADRENALIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; NORADRENALIN BLOOD LEVEL; OUTPATIENT CARE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC NERVE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CARDIOMYOPATHY, DILATED; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PYRIMIDINES; PYRROLES; STROKE VOLUME; SULFONAMIDES; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS;

EID: 80052137850     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0222     Document Type: Article

References (41)

1. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 2004; 292: 1307-1316.
2. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: Subgroup analysis of the treating to new targets (TNT) study. Circulation 2007; 115: 576-583.
3. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117: 3002-3009.
4. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
5. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebocontrolled trial. Lancet 2008; 372: 1231-1239.
6. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: Roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005; 112: 1763-1770.
7. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
8. Nishiyama K, Tsutamoto T, Yamaji M, Kawahara C, Yamamoto T, Fujii M, et al. Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure: Special reference to transcardiac gradient of norepinephrine. Circ J 2009; 73: 2270-2275.
9. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande JL, Duval AM, et al. Prognostic value of mibg imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999; 40: 917-923.
10. Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K. Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J 2001; 65: 155-160.
11. 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments: Comparison with neurohumoral factors. Circ J 2002; 66: 537-543.
12. Gerson MC, McGuire N, Wagoner LE. Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail 2003; 9: 384-391.
13. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: A systematic review. Eur Heart J 2008; 29: 1147-1159.
14. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
15. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587-1593.
16. Tsutamoto T, Sakai H, Nishiyama K, Tanaka T, Fujii M, Yamamoto T, et al. Direct comparison of transcardiac increase in brain natriuretic peptide (BNP) and N-terminal proBNP and prognosis in patients with chronic heart failure. Circ J 2007; 71: 1873-1878.
17. Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007; 28: 1723-1730.
18. Tsutamoto T, Wada A, Matsumoto T, Maeda K, Mabuchi N, Hayashi M, et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 2086-2092.
19. Ishikawa C, Tsutamoto T, Fujii M, Sakai H, Tanaka T, Horie M. Prediction of mortality by high-sensitivity c-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J 2006; 70: 857-863.
20. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, et al. Plasma n-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction: Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001; 37: 1781-1787.
21. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, et al. Prognostic impact of plasma n-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: A substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110: 1780-1786.
22. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and aminoterminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (VAL-HEFT) data. Clin Chem 2006; 52: 1528-1538.
23. Gardner RS, Chong KS, Morton JJ, McDonagh TA. A change in N-terminal pro-brain natriuretic peptide is predictive of outcome in patients with advanced heart failure. Eur J Heart Fail 2007; 9: 266-271.
24. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, et al. Prognostic value of changes in n-terminal pro-brain natriuretic peptide in VAL-HEFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008; 52: 997-1003.
25. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Schlegel TT, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Cardiac Fail 2008; 14: 140-144.
26. Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: Results from a comparative study with signalaveraged electrocardiogram, heart rate variability, and qt dispersion. J Am Coll Cardiol 2009; 53: 426-435.
27. Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007; 13: 1-7.
28. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006; 47: 332-337.
29. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Polonski L, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006; 97: 899-904.
30. Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, Abbate A, Vrtovec B, Khan BV, et al. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 2009; 104: 1708-1716.
31. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108: 839-843.
32. Yamada T, Node K, Mine T, Morita T, Kioka H, Tsukamoto Y, et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: A prospective randomized controlled study. Am Heart J 2007; 153: 1055. e1-e8.
33. Ichihara K, Satoh K. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet 2002; 359: 2195-2198.
34. Tsutsui T, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 2002; 39: 957-962.
35. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003; 107: 2493-2498.
36. Matsuki A, Nozawa T, Igarashi N, Sobajima M, Ohori T, Suzuki T, et al. Fluvastatin attenuates diabetes-induced cardiac sympathetic neuropathy in association with a decrease in oxidative stress. Circ J 2010; 74: 468-475.
37. Gomes ME, Lenders JW, Bellersen L, Verheugt FW, Smits P, Tack CJ. Sympathoinhibitory effect of statins in chronic heart failure. Clin Auton Res 2010; 20: 73-78.
38. Gomes ME, Tack CJ, Verheugt FW, Smits P, Lenders JW. Sympathoinhibition by atorvastatin in hypertensive patients. Circ J 2010; 74: 2622-2626.
39. Mason RP, Walter MF, Day CA, Jacob RF. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem 2006; 281: 9337-9345.
40. Tsutamoto T, Yamaji M, Kawahara C, Nishiyama K, Fujii M, Yamamoto T, et al. Effect of simvastatin vs. Rosuvastatin on adiponectin and haemoglobin a1c levels in patients with non-ischaemic chronic heart failure. Eur J Heart Fail 2009; 11: 1195-1201.
41. Rinfret S, Behlouli H, Eisenberg MJ, Humphries K, Tu JV, Pilote L. Class effects of statins in elderly patients with congestive heart failure: A population-based analysis. Am Heart J 2008; 155: 316-323.